Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;6(5):879-882.
doi: 10.21037/tau.2017.06.02.

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis

G Luke Machen  1 , M Hasan Rajab  1 , Jessica Pruszynski  1 , K Scott Coffield  1
Affiliations

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis

G Luke Machen et al. Transl Androl Urol. 2017 Oct.

Abstract

Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use.

Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value.

Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P<0.0001).

Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.

Keywords: Prostate cancer; erectile dysfunction (ED); phosphodiesterase inhibitors; prostate neoplasm.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Sadovsky R, Miller T, Moskowitz M, et al. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001;55:115-28. - PubMed
    1. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702. 10.1084/jem.20061104 - DOI - PMC - PubMed
    1. Hamilton TK, Hu N, Kolomitro K, et al. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. World J Urol 2013;31:325-30. 10.1007/s00345-012-0848-7 - DOI - PubMed
    1. Chavez AH, Scott Coffield K, Hasan Rajab M, et al. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. Asian J Androl 2013;15:246-8. 10.1038/aja.2012.162 - DOI - PMC - PubMed
    1. Jamnagerwalla J, Howard LE, Vidal AC, et al. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. J Urol 2016;196:715-20. 10.1016/j.juro.2016.03.172 - DOI - PMC - PubMed